 |
| Modules | |
| Google | |
|
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS. | |
| Languages | |
|
Select Interface Language:
| |
| Who''s Online | |
There are currently, 218 guest(s) and 68 member(s) that are online.
You are Anonymous user. You can register for free by clicking here | |
| Next Step | |
| Donations | |
|
To remain unbiased, This is MS does not accept corporate sponsorships. Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you! | |
| |
 | News: Aimspro Update -- It is still Alive |
 The Aimspro saga, like Tysabri, has taken many twists and turns in the past year. After posting promising anecdotal stories and interesting (though not overwhelming) trial results in the treatment of optic neuritis, the Medicines and Healthcare Products Regulation Agency (UK) seemed to have put a halt on production of the therapy. Today, the MHpRA released an update noting some interesting points:
- The agency had not put the production of Aimspro on hold, as previously reported in the press
- The agency had advised Daval International, makers of Aimspro, on how to obtain the appropriate licenses to produce Aimspro as a "special clinical need"
- The agency even pointed Daval to manufacturers who were skilled in the production of these so-called "special" therapies
- The agency is apparently trying to expedite the manufacture of Aimspro, but Daval is in control of the pace.
The first point seems rather confusing-- the agency did not put the production of the medicine on hold, but instead seems to have pointed (and enforced?) the series of licenses necessary to produce a biological agent safely.
In any case, the bottom line is that Aimspro is NOT dead, the regulatory agency seems actively involved in helping it be produced successfully and legally, and it is Daval that will be driving the pace of progress.
Click "read more" to get the full press release from the MHpRA.
Link to Press Release
http://www.mhra.gov.uk/news/Aimspro_update060705.pdf
|
|
|
|
| |
| Login | |
|
Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. | |
| Related Links | |
| Article Rating | |
Average Score: 4.14
Votes: 7
| |
| Options | |
|
|
|
